Cargando…

Rush immunotherapy in two cats with atopic skin syndrome

CASE SERIES SUMMARY: Two cats with feline atopic skin syndrome (FASS) were included in this case series. They were diagnosed with FASS by a combination of history, physical examination and exclusion of other pruritic diseases. They underwent rush immunotherapy (RIT) after determination of offending...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Selene, Bloom, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221683/
https://www.ncbi.nlm.nih.gov/pubmed/34221441
http://dx.doi.org/10.1177/20551169211023327
_version_ 1783711369486401536
author Jones, Selene
Bloom, Paul
author_facet Jones, Selene
Bloom, Paul
author_sort Jones, Selene
collection PubMed
description CASE SERIES SUMMARY: Two cats with feline atopic skin syndrome (FASS) were included in this case series. They were diagnosed with FASS by a combination of history, physical examination and exclusion of other pruritic diseases. They underwent rush immunotherapy (RIT) after determination of offending environmental allergens by either serum IgE or intradermal testing. Cats were premedicated with an antihistamine and hospitalized for the day to undergo the procedure and to ensure adequate observation. Allergen extracts were administered subcutaneously at increasing concentrations every 30 mins until the maintenance dose of 20,000 protein nitrogen units/ml was reached. Both cats successfully completed RIT without any adverse reactions and their clinical signs improved afterwards. RIT appears to be an alternative treatment option for cats with FASS. Larger studies are needed to more accurately assess the safety and long-term efficacy of RIT in the feline patient, as well as the incidence of adverse reactions and optimal premedication protocol. Further evaluation of the route of injections for RIT is also warranted. RELEVANCE AND NOVEL INFORMATION: RIT has been reported to be a safe treatment option in canine atopic dermatitis. Its use in FASS is limited to a pilot study of four cats. The purpose of this series was to describe two additional cats that underwent RIT using a different premedication protocol.
format Online
Article
Text
id pubmed-8221683
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-82216832021-07-01 Rush immunotherapy in two cats with atopic skin syndrome Jones, Selene Bloom, Paul JFMS Open Rep Case Series CASE SERIES SUMMARY: Two cats with feline atopic skin syndrome (FASS) were included in this case series. They were diagnosed with FASS by a combination of history, physical examination and exclusion of other pruritic diseases. They underwent rush immunotherapy (RIT) after determination of offending environmental allergens by either serum IgE or intradermal testing. Cats were premedicated with an antihistamine and hospitalized for the day to undergo the procedure and to ensure adequate observation. Allergen extracts were administered subcutaneously at increasing concentrations every 30 mins until the maintenance dose of 20,000 protein nitrogen units/ml was reached. Both cats successfully completed RIT without any adverse reactions and their clinical signs improved afterwards. RIT appears to be an alternative treatment option for cats with FASS. Larger studies are needed to more accurately assess the safety and long-term efficacy of RIT in the feline patient, as well as the incidence of adverse reactions and optimal premedication protocol. Further evaluation of the route of injections for RIT is also warranted. RELEVANCE AND NOVEL INFORMATION: RIT has been reported to be a safe treatment option in canine atopic dermatitis. Its use in FASS is limited to a pilot study of four cats. The purpose of this series was to describe two additional cats that underwent RIT using a different premedication protocol. SAGE Publications 2021-06-21 /pmc/articles/PMC8221683/ /pubmed/34221441 http://dx.doi.org/10.1177/20551169211023327 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Series
Jones, Selene
Bloom, Paul
Rush immunotherapy in two cats with atopic skin syndrome
title Rush immunotherapy in two cats with atopic skin syndrome
title_full Rush immunotherapy in two cats with atopic skin syndrome
title_fullStr Rush immunotherapy in two cats with atopic skin syndrome
title_full_unstemmed Rush immunotherapy in two cats with atopic skin syndrome
title_short Rush immunotherapy in two cats with atopic skin syndrome
title_sort rush immunotherapy in two cats with atopic skin syndrome
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221683/
https://www.ncbi.nlm.nih.gov/pubmed/34221441
http://dx.doi.org/10.1177/20551169211023327
work_keys_str_mv AT jonesselene rushimmunotherapyintwocatswithatopicskinsyndrome
AT bloompaul rushimmunotherapyintwocatswithatopicskinsyndrome